EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing

Xiaoqing Yu, Michael D Jain, Meghan A Menges, Ling Cen, Jerald D Noble, Reginald Atkins, Turab J Mohammad, Christina A Bachmeier, Samira Naderinezhad, Kayla Reid, Salvatore Corallo, Sean J Yoder und 13 weitere

Journal for ImmunoTherapy of Cancer · 2025-07 · 13 (7) · e011807

DOI: 10.1136/jitc-2025-011807 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.07.2025. Verfasst von Xiaoqing Yu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Leukemia and Lymphoma Society, Division of Cancer Prevention, National Cancer Institute, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Among approved CAR T-cell products, axicabtagene ciloleucel (axi-cel; CD19/CD28) has greater real-world efficacy and cytokine-associated toxicity than tisagenlecleucel (tisa-cel; CD19/4-1BB), for reasons that are poorly understood.

Methods

Here we report single-cell RNA sequencing (scRNA-seq) of 57 pre-infusion CAR T-cell products from axi-cel (n=39) and tisa-cel (n=18) patients treated as standard-of-care for R/R LBCL, and their biological associations with clinical outcomes. In vitro CAR manufacturing conditions mimicking those known for axi-cel and tisa-cel were performed using CD19/CD28z or CD19/4-1BBz constructs.

Results

ScRNA-seq revealed that axi-cel and tisa-cel are markedly different products. Axi-cel is comprised of more CD4 central memory, CD8 central memory, and CD8 effectors, whereas tisa-cel is comprised of more proliferative CD4 and CD8 cells. Across multiple T-cell subsets, axi-cel had greater expression of immune response pathways and protein synthesis and trafficking pathways versus tisa-cel. On comparison of infusion product CAR transgene-positive (CAR+) cells to CAR transgene-negative (CAR−) T cells, axi-cel CAR+ cells had vastly different gene expression than axi-cel CAR− cells. Unexpectedly, tisa-cel CAR+ cells were highly similar to tisa-cel CAR− cells. Under recapitulated CAR-T manufacturing conditions known to be used for axi-cel and tisa-cel, we found that CAR+ cells differed from CAR− cells early after manufacturing yet became more similar to CAR− cells after prolonged expansion. Prolonged time in expansion culture, as used during tisa-cel manufacturing, greatly decreased naïve and central memory T-cell subsets.

Conclusions

Following manufacture, axi-cel is less differentiated and has greater immune activation compared with tisa-cel, potentially accounting for its greater efficacy and toxicity in patients. Our data support the conclusion that tisa-cel is adversely affected by its manufacturing rather than by the CAR construct.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Antigen, T-CellReceptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansFemaleMaleMiddle AgedAntigens, CD19Single-Cell AnalysisAgedAdultSequence Analysis, RNABiological Products

Stichwörter der Autor:innen

Chimeric antigen receptor - CARLymphomaT cell

Substanzen

axicabtagene ciloleuceltisagenlecleucelReceptors, Antigen, T-CellAntigens, CD19Receptors, Chimeric AntigenBiological Products

Autor:innen und Institutionen

  • Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA.
  • Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA.
  • Clinical Science, Moffitt Cancer Center, Tampa, Florida, USA.
  • Molecular Genomics Core, Moffitt Cancer Center, Tampa, Florida, USA.
  • Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Tumor Biology, Moffitt Cancer Center, Tampa, Florida, USA.

Förderung

  • Leukemia and Lymphoma Society
  • Division of Cancer Prevention, National Cancer Institute
  • NIH
  • Mark Foundation For Cancer Research
  • Florida Department of Health

Zitieren

APA

Yu, X., Jain, M. D., Menges, M. A., Cen, L., Noble, J. D., Atkins, R., Mohammad, T. J., Bachmeier, C. A., Naderinezhad, S., Reid, K., Corallo, S., Yoder, S. J., Zhang, C., Zhang, L., Miranda, J. A., Shah, B., Chavez, J. C., Hesterberg, R. S., Delgado, L. C., …, & Locke, F. L. (2025). Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. Journal for ImmunoTherapy of Cancer, 13(7), e011807. https://doi.org/10.1136/jitc-2025-011807

Vancouver

Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, et al. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. Journal for ImmunoTherapy of Cancer. 2025;13(7):e011807. doi:10.1136/jitc-2025-011807

BibTeX
@article{Yu2025,
  author = {Yu, Xiaoqing and Jain, Michael D and Menges, Meghan A and Cen, Ling and Noble, Jerald D and Atkins, Reginald and Mohammad, Turab J and Bachmeier, Christina A and Naderinezhad, Samira and Reid, Kayla and Corallo, Salvatore and Yoder, Sean J and Zhang, Chaomei and Zhang, Lanmin and Miranda, Julieta Abraham and Shah, Bijal and Chavez, Julio C and Hesterberg, Rebecca S and Delgado, Luis Cuadrado and Savid-Frontera, Constanza and Rodriguez, Paulo C and Cleveland, John L and Wang, Xuefeng and Davila, Marco L and Locke, Frederick L},
  title = {Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {7},
  pages = {e011807},
  doi = {10.1136/jitc-2025-011807}
}
Kostenlos starten →